Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, William Plunkett et al.|New England Journal of Medicine|2019Cited by 502
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaGuillermo Garcia‐Manero, Jean‐Pierre J. Issa, Hagop M. Kantarjian et al.|Blood|2006Cited by 468
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemiaAlessandra Ferrajoli, George A. Călin, Tait D. Shanafelt et al.|Blood|2013Cited by 220
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cellsInbal Hazan‐Halevy, Zeev Estrov|Blood|2010Cited by 196